Menu Search
Equities

OncoTherapy Science Inc

30O:BER

OncoTherapy Science Inc

Actions
  • Price (EUR)0.11
  • Today's Change-0.024 / -17.91%
  • Shares traded-1.00
  • 1 Year change-47.12%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 07:15 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

  • Revenue in JPY (TTM)610.12m
  • Net income in JPY-1.29bn
  • Incorporated2001
  • Employees60.00
  • Location
    OncoTherapy Science Inc1-2, Higashida-cho, Kawasaki-kuKAWASAKI-SHI 210-0005JapanJPN
  • Phone+81 442016429
  • Fax+81 442016473
  • Websitehttps://www.oncotherapy.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.